<SEC-DOCUMENT>0001193125-19-154569.txt : 20190523
<SEC-HEADER>0001193125-19-154569.hdr.sgml : 20190523
<ACCEPTANCE-DATETIME>20190523062704
ACCESSION NUMBER:		0001193125-19-154569
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190523
FILED AS OF DATE:		20190523
DATE AS OF CHANGE:		20190523

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		19847916

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d765189d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated May 23, 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by
furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Immutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May 23, 2019 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U></U>Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d765189dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g765189g48c57.gif" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP ANNOUNCES EUROPEAN PATENT GRANT FOR EFTILAGIMOD ALPHA IN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHEMO-IMMUNOTHERAPY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA
&#150; </B><B>23</B><B></B><B>&nbsp;May 2019 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune
diseases, is pleased to announce the grant of a new patent (number<B> </B>3089749) entitled &#147;Combined Preparations for the Treatment of Cancer&#148; by the European Patent Office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The new patent protects Immutep&#146;s intellectual property relating to combined therapeutic preparations comprising its lead active immunotherapy candidate
eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;) and a chemotherapy agent. The chemotherapy agent is either a platinum-based anti-neoplastic agent, such as oxaliplatin or carboplatin, or a topoisomerase I inhibitor, such as topotecan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Fr&eacute;d&eacute;ric Triebel, Immutep CSO and CMO, commented, &#147;This new patent is important because platinum-based chemotherapy agents and
topoisomerase I inhibitors continue to be commonly used forms of chemotherapy. In addition, the past couple of years has seen, for the first time, the marketing approval and adoption of first or second line combinations of chemotherapy and active
immunotherapies for the treatment of advanced solid tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As such, this new patent provides patent protection in Europe for a range of novel and highly
relevant chemo-immunotherapies featuring efti that may be pursued in the future.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent expiry date is 19&nbsp;December 2034. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology
company that is a leader in the development of immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for
patients and to maximize value to shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a
soluble <FONT STYLE="white-space:nowrap">LAG-3Ig</FONT> fusion protein based on the <FONT STYLE="white-space:nowrap">LAG-3</FONT> immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is
currently in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT02614833); a Phase II clinical trial referred to as <FONT STYLE="white-space:nowrap">TACTI-002</FONT> (Two
ACTive Immunotherapies) to evaluate a combination of efti with KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); a planned Phase I
clinical trial referred to as <FONT STYLE="white-space:nowrap">INSIGHT-004</FONT> to evaluate a combination of efti with avelumab (clinical trials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed
TACTI-mel (clinicaltrials.gov identifier NCT02676869). </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g765189g48c57.gif" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products, including antibodies, for immune response
modulation in autoimmunity and cancer are being developed by Immutep&#146;s large pharmaceutical partners. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Gregorowski,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 2 8234 0105; <U>mgregorowski@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay Campbell, Chief Business Officer,
Immutep Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (917) <FONT STYLE="white-space:nowrap">860-9404;</FONT> <U>jay.campbell@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Garth Russell, LifeSci Advisors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646) <FONT
STYLE="white-space:nowrap">876-3613;</FONT> <U>garth@lifesciadvisors.com</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g765189g48c57.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g765189g48c57.gif
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MO7.UC&.U<YS&I0
M
M
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M5W>H,C^?IW/#Q KM-PBE0CL/L%/ IS8]4SMXDWJ&H'_[_J9VQV)^ T JDP$
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..CN[XCO 8C_+(#8$  #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
